Qingdao Haier BiomedicalLtd (SHSE:688139) Has A Pretty Healthy Balance Sheet

Simply Wall StNov 1 21:57 ET

Haier Biotech 2024 Third Quarter Report

SZSIOct 29 12:00 ET · Announcements

qingdao haier biomedical co., ltd. (688139.SH): Net income in the first three quarters was approximately 0.309 billion yuan, a decrease of 13.45% year-on-year.

Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced on October 29th that its revenue in the first three quarters of 2024 was approximately 1.782 billion yuan, a decrease of 2.43% year-on-year; the net income attributable to shareholders of the listed company was approximately 0.309 billion yuan, a decrease of 13.45% year-on-year.

Gelonghui FinanceOct 29 10:30 ET

Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) 11% Loss Last Week Hit Both Individual Investors Who Own 41% as Well as Institutions

Simply Wall StOct 14 20:59 ET

Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Shares Not Telling The Full Story

Simply Wall StSep 23 19:33 ET

Qingdao Haier Biomedical Co., Ltd. (688139.SH): Cumulative repurchase of 0.44% of the company's shares.

Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced on September 2nd that as of August 31, 2024, the company has repurchased a total of 1,387,844 shares of the company through the centralized bidding trading method on the Shanghai Stock Exchange, accounting for 0.44% of the total share capital of 317,952,508 shares. The highest price of the repurchase transaction was 32.31 yuan/share, the lowest price was 24.64 yuan/share, and the total amount of funds paid was 40,435,425.54 yuan (excluding transaction costs).

Gelonghui FinanceSep 2 06:15 ET